Prognostic and predictive study of circulating tumor cells (CTC) in lung adenocarcinoma. In vivo assessment of the role of Id1 and Id3 in metastatic capacity of CTCs (Q3153633): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Liquid biopsies allow detecting a tumor and knowing its evolution with just one blood test. The development of diagnostic, prognostic and predictive biomarkers of response in these samples is of great relevance for the good clinical management of patients with tumor types with high prevalence and mortality, such as lung cancer. In this prospective study we propose to validate the prognostic and predictive value of the count at diagnosis, and its...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Prognostic and predictive study of circulating tumor cells (CTC) in lung adenocarcinoma. In vivo assessment of the role of Id1 and Id3 in metastatic capacity of CTCs | |||
Revision as of 15:22, 12 October 2021
Project Q3153633 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Prognostic and predictive study of circulating tumor cells (CTC) in lung adenocarcinoma. In vivo assessment of the role of Id1 and Id3 in metastatic capacity of CTCs |
Project Q3153633 in Spain |
Statements
38,250.0 Euro
0 references
76,500.0 Euro
0 references
50.0 percent
0 references
1 January 2016
0 references
30 September 2020
0 references
FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE NAVARRA
0 references
42°49'6.42"N, 1°38'39.34"W
0 references
31201
0 references
Las biopsias líquidas permiten detectar un tumor y conocer su evolución con sólo un análisis sanguíneo. El desarrollo de biomarcadores diagnósticos, pronósticos y predictivos de respuesta en estas muestras es de gran relevancia para el buen manejo clínico de los pacientes con tipos tumorales con alta prevalencia y mortalidad, como el cáncer de pulmón. En este estudio prospectivo proponemos validar el valor pronóstico y predictivo del recuento al diagnóstico, y de su modificación durante el tratamiento, de las células tumorales circulantes (CTC) en pacientes con adenocarcinoma de pulmón estadio IV. Evaluaremos si la expresión de proteínas prometastásicas, como los Inhibidores de la Diferenciación de tipo 1 (Id1) y 3 (Id3) contribuye a la capacidad metastásica de las CTC. Estudiaremos si las mutaciones de EGFR modifican el comportamiento y/o la capacidad metastásica in vivo de las CTC y si éstas se relacionan con la expresión de Id1 e Id3. Para ello, en una primera etapa, llevaremos a cabo la selección, previa al inicio del tratamiento oncológico sistémico, de 108 pacientes con adenocarcinoma de pulmón avanzado (estadio IV): 74 con tumores nativos para EGFR y 34 con EGFR mutado. En todos ellos se extraerá sangre al diagnóstico y tras el tratamiento para cuantificación, aislamiento y cultivo de CTC. Se creará un modelo murino metastásico con CTC aisladas y se estudiará mediante silenciamiento el papel de Id1/Id3 en su capacidad metastásica. (Spanish)
0 references
Liquid biopsies allow detecting a tumor and knowing its evolution with just one blood test. The development of diagnostic, prognostic and predictive biomarkers of response in these samples is of great relevance for the good clinical management of patients with tumor types with high prevalence and mortality, such as lung cancer. In this prospective study we propose to validate the prognostic and predictive value of the count at diagnosis, and its modification during treatment, of circulating tumor cells (TCC) in patients with stage IV lung adenocarcinoma. We will evaluate whether the expression of prometstatic proteins, such as Type 1 (Id1) and 3 (Id3) Differentiation Inhibitors, contributes to the metastatic capacity of CTCs. We will study whether EGFR mutations change the behavior or metastatic capacity of CTCs and whether they are related to the expression of Id1 and Id3. To do this, in a first stage, we will carry out the selection, prior to the initiation of systemic oncological treatment, of 108 patients with advanced lung adenocarcinoma (Stage IV): 74 with native tumors for EGFR and 34 with mutated EGFR. In all of them blood will be extracted at diagnosis and after treatment for quantification, isolation and culture of CTC. A metastatic murine model with isolated CTCs will be created and the role of Id1/Id3 in its metastatic capacity will be studied by silencing. (English)
12 October 2021
0 references
Pamplona/Iruña
0 references
Identifiers
PI15_02223
0 references